AbbVie Biotech Ventures, Inc. (ABVI) is a subsidiary of AbbVie dedicated to making venture capital investments in emerging biotech and pharmaceutical companies. Unlike traditional venture capital firms, ABVI characterizes an investment's success by its potential to significantly increase AbbVie's strategic growth, and not solely by its financial return. Companies with programs ranging from pre-clinical (18 months prior to first-in-human) to early proof-of-concept are of highest interest for potential investment by ABVI. ABVI invests in technologies that are strategic to AbbVie such as neuroscience, immunology, virology, and oncology, as well as emerging or more opportunistic areas of innovation that have the potential to complement AbbVie's existing portfolio or to expand AbbVie's future business reach. The initial investment can range from several hundred thousand dollars up to several million, depending on the opportunity and development stage. However, ABVI will always remain a minority investor.